S, a multisystem granulomatous disorder of unknown aetiology, can co-exist with other connective tissue diseases, although this was once considered rare. We report on the cases of five patients who developed systemic sclerosis and sarcoidosis ('associated connective tissue diseases').
The distinctive characteristics of this association are emphasized. Remarkable features in our patients included unusually severe pulmonary symptoms, progressive worsening of lung function (leading to death in two cases) and poor efficacy of corticosteroids. The two diseases developed simultaneously in three patients. Fourteen previously reported cases form the basis for a discussion of clinical aspects, aetiology and the possible need to reconsider the name 'sarcoidosis'.
PATIENTS
Five patients with systemic sclerosis (SS) and sarcoidosis (SA) were evaluated. Demographic, clinical and laboratory data on these patients are reported in Tables I-III . There were three females and two males; two patients were Caucasians, one was from the Caribbean, one was Asian and one was Indian. All five patients had diffuse SS. The onset of SS was defined as the date of occurrence of the first symptom other than Raynaud's phenomenon. SS antedated SA in three cases and postdated SA in two. Clinical features are summarized in Tables II and III . In patients 1, 3 and 4, interstitial lung disease was present at diagnosis of SA; in these three cases, at least, there was incontrovertible evidence that the two diseases (SS and SA) co-existed.
The diagnosis of SA was made in each case only after negative results were obtained from intensive investigations for opportunistic infections (e.g. fungi and mycobacteria), foreign body diseases and other aetiologies for chronic granulomatous sarcoid-like diseases. In all patients, at least one biopsy specimen exhibited typical features of SA, with non-caseating epitheloid granulomas and multinucleated giant cells.
Patient 4 had a history of possible silica exposure, since he worked in a sand mould factory for 2 yr. SA was diagnosed when he experienced increased respiratory discomfort. Silica was not found in pulmonary biopsies or bronchoalveolar lavage (BAL) specimens. BAL fluid showed an increased cell count (770 000/ml) with 21% lymphocytes, 20% neutrophils and 3% mast cells. This patient had a history of multiple bouts of pulmonary superinfection and progressive worsening of respiratory function. He died of acute legionellosis 6 yr after the onset of SS. The postmortem study showed diffuse sarcoid lesions (see Table II) .
Patient 3 had a mild form of SS. SA was diagnosed upon evaluation of typical Lo¨fgren's syndrome. She also had sicca syndrome with positive anti-SSA and SSB autoantibodies. BAL showed an increased cell count (405 000/ml) with 7% lymphocytes and a CD4/CD8 ratio of 4.8. She had multiple bouts of exacerbation of lung dysfunction and was treated with high doses of prednisone, which were tapered between flares. However, conclusive evidence of a link between these flares and SS or SA could not be obtained because she refused further endoscopic examination and BAL. She died of cardiogenic shock 5 yr after the diagnosis of SA during the postoperative period of pneumonectomy for adenocarcinoma of the lung. Patients 1 and 5 are doing well, 2 and 12 yr, respectively, after the diagnosis of SS. Patient 2 has an aggressive form of SS with renal and cardiac involvement requiring recurrent prostacyclin infusions, but her pulmonary function tests are stable 7 yr after the diagnosis of SS.
Pulmonary function tests performed within 3 months after SA onset documented mild restrictive defects in patients who developed SS before SA (patients 1, 3 and 4), with the most severely affected parameter being the diffusing capacity of the lung for carbon monoxide (mean 53% of the predicted value). In the two other patients (SA antedating SS), lung function tests were normal or showed mild obstructive dysfunction.
DISCUSSION
We report five patients with SS and SA. This association is apparently rare, since a review of the literature found only 14 other cases [1] [2] [3] [4] [5] [6] .
Demographic and clinical features in the 19 patients were as follows: sex: 12 females and seven males; race: 12 Caucasians, three blacks, two Asians, one Indian and one unknown; mean age at onset of SS: 48 yr (range 29-74); mean age at SA onset: 50 yr (range 23-76). SS onset antedated SA by 1-30 yr (mean eight) in 11 cases, postdated SA in two cases (by 4 and 10 yr), and coincided with the diagnosis of SA in six cases. Co-existing active diseases were documented in at least eight cases. SS was limited in 10 cases and diffuse in nine. Tests for antinuclear autoantibodies were positive, with a speckled pattern, in 17 patients, negative in one and not carried out in one; anti-ScL-70 autoantibodies were detected in six of 16 patients and were not looked for in three; four patients had anti-centromere autoantibodies, one had rheumatoid factor, and one had anti-SSA and anti-SSB autoantibodies.
Intrathoracic lymphadenopathy was documented in 13 patients, including six with bilateral hilar lymphadenopathy over prolonged periods of time. Radiological interstitial lung disease was present in most patients at diagnosis of SA. The diagnosis of SA was usually established upon evaluation for fever and/or exacerbation of respiratory symptoms (with only one case of Lo¨fgren's syndrome). The development of severe respiratory failure was rare.
A number of clinical aspects and unsettled issues deserve to be emphasized. First, in two of the 19 patients, SS occurred several years after extinction of SA; in our opinion, these patients do not meet the definition of 'associated connective tissue diseases'.
The onset of 'sarcoidosis' in a patient with preexisting or concurrent SS is of greater interest. At least eight of 17 patients (47%) were in this situation. These patients had true 'associated connective tissue diseases'. To date, there is no proven means of determining which of the two diseases is responsible for the flares seen in such patients, although this is of considerable practical importance. Second, we do not know whether these patients are best treated by prednisone or by immunosuppressive drugs. In the literature, there are no conclusive data on the contribution of each disease to the symptoms. BAL cannot solve this problem. The clinical and functional status of these patients was improved or stabilized by prednisone therapy alone, and only one patient received immunosuppressive drugs. In our experience (cases 3 and 4), prednisone was ineffective, and we were unable to determine the cause of the flares (except when these were due to infections). Were our patients different from those in the literature? We suggest that methotrexate may be beneficial in this situation since it seems to be effective in both SA and scleroderma [8, 9] .
Is the co-existence of SA and SS of adverse prognostic significance? In our experience, patients who develop SA after SS have a poor prognosis, but the number of our cases is small. We believe that other cases of the SA-SS association should be reported to provide additional clinical and prognostic data.
Do patients with 'sarcoidosis' and SS have true SA or sarcoid-like diseases? Patients with SS frequently have a history of exposure to silica [1, 7] . Pulmonary silicosis is responsible for various patterns of presentation, and the high incidence of intrathoracic lymphadenopathy reported by Cox (58% in diffuse scleroderma and 42% in limited forms) supports a link between silica exposure and scleroderma. Also in favour of such a link is the long duration of intrathoracic lymphadenopathy in some patients. Furthermore, the simultaneous onset of SA and SS in six cases is consistent with a common aetiology. Histopathological features of SA are not specific and can be encountered in many other diseases; moreover, high blood levels of angiotensin-converting enzyme occur not only in SA, but also in other granulomatous diseases. Thus, other granulomatous diseases (especially due to silica) should be carefully looked for in patients with suspected SA. It remains to be determined whether the investigations carried out in the 14 previously reported cases of the SA-SS association were adequate to rule out confidently granulomatous diseases other than SA.
The very low incidence of the SA-SS association may militate against a chance association, given the incidence of pulmonary SA (100/million/year) and the incidence of SS (3/million/year) [10, 11] .
In conclusion, 'sarcoidosis' associated with SS seems (in our experience) to be severe and persistent, as illustrated by our patients 3 and 4. In these patients, the main clinical problem was to determine which disease was responsible for the flares. The optimal treatment in this situation remains unknown, and studies are needed to evaluate the value of immunosuppressive agents. Finally, we established the diagnosis of 'sarcoidosis' associated with SS based on a set of converging arguments, but it may be more appropriate to use the term 'sarcoid-like disease associated with systemic sclerosis' until incontrovertible evidence of the aetiology(ies) of this association is obtained.
